Somalogic, Incorporated

Quest Diagnostics Investments, Inc.

Deborah Ayers

Weimin Sun

Charles M Strom

Chris Bock

Malti P Nikrad

Bharat Nathu Gawande

Jennifer C Bertino

Noh Jin Park

Larry M Gold

Nebojsa Janjic

Thale Jarvis

Sheri K Wilcox

Michael Riel-Mehan

The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.

Lung cancer biomarkers and uses thereof

The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3' cap. In some embodiments, the 3&#x2032; cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5&#x2032;-end of the aptamer and the moiety is attached the 5&#x2032; end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore.

Aptamers and diagnostic methods for detecting the EGF receptor

Growing community of inventors

Broomfield, CO, United States of America

Deborah Ayers